| | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = $31,303,993 ) (Continued on the next page) |
| | 2021 | 2021 | R01HL148827 | Discovery of small molecule promoters of cardiomyocyte proliferation to restore cardiac performance in disease | 000 | 2 | NIH | 2/19/2021 | 020520466 | $11,441 |
| | 2021 | 2021 | R01HL148827 | Discovery of small molecule promoters of cardiomyocyte proliferation to restore cardiac performance in disease | 001 | 3 | NIH | 4/24/2021 | 020520466 | $487,500 |
| | 2021 | 2021 | R01HL148827 | Discovery of small molecule promoters of cardiomyocyte proliferation to restore cardiac performance in disease | 003 | 3 | NIH | 5/12/2021 | 020520466 | $44,979 |
| | 2021 | 2021 | R01NS105969 | Brain pathology and function in a chronic mouse model of ZIKV transmission | 000 | 3 | NIH | 4/2/2021 | 020520466 | $655,075 |
| | 2021 | 2021 | R01AG062190 | "A Novel Role for the UPR Component, ATF6 in AD-associated Neuroprotective Pathways" | 000 | 3 | NIH | 2/16/2021 | 020520466 | $971,032 |
| | 2021 | 2021 | R01HL141880 | Mechanisms of hematopoietic acute radiation syndrome induction and radioprotection through sphingosine 1-phosphate receptor 1 signal modulation | 000 | 4 | NIH | 6/25/2021 | 020520466 | $487,500 |
| | 2021 | 2021 | R01NS103940 | S1P signaling machinery in neuroimmune interactions | 000 | 4 | NIH | 2/10/2021 | 020520466 | $426,563 |
| | 2021 | 2021 | R35GM118186 | Membrane Protein Effectors of Pathogen Interactions With Host | 000 | 6 | NIH | 5/12/2021 | 020520466 | $809,250 |
| | 2021 | 2021 | P30CA030199 | Cancer Center Support Grant (CCSG) | 005 | 40 | NIH | 4/30/2021 | 020520466 | $4,081,820 |
| | 2021 | 2021 | R01AG071861 | Cytoplasmic chromatin fragments in cell senescence - novel mechanisms and interventions | 000 | 1 | NIH | 4/30/2021 | 020520466 | $628,610 |
| | 2021 | 2021 | R21CA249822 | Multi-strain, live biotherapeutics as adjuncts to checkpoint inhibitor therapy | 000 | 1 | NIH | 5/17/2021 | 020520466 | $263,086 |
| | 2021 | 2021 | R21CA249822 | Multi-strain, live biotherapeutics as adjuncts to checkpoint inhibitor therapy | 001 | 1 | NIH | 5/28/2021 | 020520466 | $0 |
| | 2021 | 2021 | R03CA252144 | Targeting Checkpoint Inhibition in Anti-Tumor Responses | 000 | 1 | NIH | 3/15/2021 | 020520466 | $97,500 |
| | 2021 | 2021 | R01AG065387 | Development of STEP Allosteric Inhibitors as Novel Therapeutics for Alzheimer's Disease | 000 | 2 | NIH | 5/25/2021 | 020520466 | $902,529 |
| | 2021 | 2021 | R01DK099551 | New Congenital Disorders of Glycosylation: Therapy and Models | 001 | 8 | NIH | 6/11/2021 | 020520466 | $0 |
| | 2021 | 2021 | R01HL054732 | Genetic Control of Cardiac Development: Congenital Heart Disease Gene Discovery in Drosophila | 002 | 24 | NIH | 6/15/2021 | 020520466 | $2,207 |
| | 2021 | 2021 | R01HL054732 | Genetic Control of Cardiac Development: Congenital Heart Disease Gene Discovery in Drosophila | 000 | 24 | NIH | 6/11/2021 | 020520466 | $838,927 |
| | 2021 | 2021 | R01CA159859 | Mouse models to discover new drivers of medulloblastoma | 000 | 10 | NIH | 1/26/2021 | 020520466 | $746,845 |
| | 2021 | 2021 | R01CA216187 | Linking the microbiome and immune-checkpoint in melanoma by RNF5 | 000 | 5 | NIH | 2/24/2021 | 020520466 | $603,580 |
| | 2021 | 2021 | R01AI127302 | Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection | 000 | 5 | NIH | 1/15/2021 | 020520466 | $860,576 |
| | 2021 | 2021 | R01DK048247 | Glycosyltransferase Function in Development and Disease | 000 | 24 | NIH | 3/17/2021 | 020520466 | $487,500 |
| | 2021 | 2021 | R21CA244028 | Nuclear pore regulation of leukemia cell metabolism and survival | 000 | 2 | NIH | 11/20/2020 | 020520466 | $216,510 |
| | 2021 | 2021 | R21CA244028 | Nuclear pore regulation of leukemia cell metabolism and survival | 001 | 2 | NIH | 1/22/2021 | 020520466 | $11,396 |
| | 2021 | 2021 | R01AR077448 | Role of Fbxw7-Mediated Proteasomal Degradation in Myofibers in Determining Muscle Stem Cell Pool Size | 000 | 2 | NIH | 6/25/2021 | 020520466 | $631,856 |
| | 2021 | 2021 | K99AG066960 | A Role of Astrocyte and Microglia Interplay in Alzheimer's Disease | 000 | 2 | NIH | 6/30/2021 | 020520466 | $129,870 |
| | 2021 | 2021 | R21AG068913 | Phenotypic Screening for Longevity Interventions Using Single-cell Epigenetic Signatures | 000 | 2 | NIH | 5/13/2021 | 020520466 | $243,750 |
| | 2021 | 2021 | R01AI151371 | Protein Sialylation and De-Sialyation in Cell Surface Glycoprotein Homeostasis and Disease | 001 | 1 | NIH | 3/16/2021 | 020520466 | -$487,500 |
| | 2021 | 2021 | R01AI151371 | Protein Sialylation and De-Sialyation in Cell Surface Glycoprotein Homeostasis and Disease | 001 | 1 | NIH | 3/16/2021 | 020520466 | $487,500 |
| | 2021 | 2021 | R01AI151371 | Protein Sialylation and De-Sialyation in Cell Surface Glycoprotein Homeostasis and Disease | 000 | 1 | NIH | 1/29/2021 | 020520466 | $487,500 |
| | 2021 | 2021 | R01HL153645 | Discovery of small molecule regulators of atrial cardiomyocyte action potential duration to restore normal cardiac rhythm in atrial fibrillation | 000 | 1 | NIH | 6/7/2021 | 020520466 | $487,500 |
| | 2021 | 2021 | T32AI125209 | Frontiers in Fundamental and Translational Immunology | 001 | 4 | NIH | 3/17/2021 | 020520466 | $3,499 |
| | 2021 | 2021 | T32AI125209 | Frontiers in Fundamental and Translational Immunology | 000 | 4 | NIH | 12/11/2020 | 020520466 | $185,818 |
| | 2021 | 2021 | R01GM131374 | Ligand functional selectivity in EphA2 receptor signaling | 001 | 3 | NIH | 2/16/2021 | 020520466 | $45,988 |
| | 2021 | 2021 | R01GM131374 | Ligand functional selectivity in EphA2 receptor signaling | 000 | 3 | NIH | 11/10/2020 | 020520466 | $413,889 |
| | 2021 | 2021 | R01DK117133 | The Development of TGR5 Antagonists for the Treatment of Cholangiopathies | 000 | 3 | NIH | 6/16/2021 | 020520466 | $491,856 |
| | 2021 | 2021 | R01AI148668 | Characterizing the nuclear pore complex-T cell receptor connection | 000 | 2 | NIH | 11/17/2020 | 020520466 | $653,587 |
| | 2021 | 2021 | R01CA237536 | Non-Canonical Phosphatidylinositol Kinases in Triple Negative Breast Cancer | 000 | 2 | NIH | 5/3/2021 | 020520466 | $446,063 |
| | 2021 | 2021 | S10OD030285 | Digital Spatial Profiler Analysis Instrument | 000 | 1 | NIH | 4/9/2021 | 020520466 | $302,469 |
| | 2021 | 2021 | F32HL156607 | Identifying novel networks of candidate Atrial Fibrillation genes in the Drosophila cardiac aging model | 001 | 1 | NIH | 3/19/2021 | 020520466 | $0 |
| | 2021 | 2021 | F32HL156607 | Identifying novel networks of candidate Atrial Fibrillation genes in the Drosophila cardiac aging model | 000 | 1 | NIH | 3/19/2021 | 020520466 | $68,562 |
| | 2021 | 2021 | R21ES032583 | Role of Epigenetically Active Environmental Compounds in Neurodevelopmental Disorders | 000 | 1 | NIH | 4/20/2021 | 020520466 | $195,000 |
| | 2021 | 2021 | R21AI160161 | Targeting the VHR phosphatase for the treatment of sepsis in COVID-19 patients | 000 | 1 | NIH | 4/6/2021 | 020520466 | $292,500 |
| | 2021 | 2021 | R21AI160161 | Targeting the VHR phosphatase for the treatment of sepsis in COVID-19 patients | 001 | 1 | NIH | 4/7/2021 | 020520466 | $0 |
| | 2021 | 2021 | R01CA229818 | Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors | 000 | 4 | NIH | 6/7/2021 | 020520466 | $714,132 |
| | 2021 | 2021 | T32CA211036 | Cancer Targets and Drug Discovery | 002 | 4 | NIH | 7/1/2021 | 020520466 | $253,774 |
| | 2021 | 2021 | R01AG061875 | Novel roles for the Alzheimer's Disease (AD) risk gene, SORLA in neuroprotection in AD | 000 | 4 | NIH | 5/12/2021 | 020520466 | $681,080 |
| | 2021 | 2021 | R01AR076247 | Denervation activated super-enhancers of pathogenic IL6-STAT3 feedforward loop in FAPs | 000 | 3 | NIH | 5/24/2021 | 020520466 | $416,130 |
| | 2021 | 2021 | R35CA197465 | Rewired Signaling at the Nexus of Melanoma Metastasis and Resistance | 000 | 6 | NIH | 1/29/2021 | 020520466 | $1,129,373 |
| | 2021 | 2021 | R21CA249353 | Modulation of metabolism in TILs by the checkpoint inhibitor PSGL-1 | 000 | 2 | NIH | 1/29/2021 | 020520466 | $227,906 |
|
